Illumina, Inc. (NASDAQ:ILMN - Get Free Report) saw some unusual options trading on Tuesday. Investors acquired 6,321 put options on the company. This is an increase of approximately 50% compared to the typical daily volume of 4,204 put options.
Illumina Trading Down 2.9 %
Shares of ILMN stock traded down $3.47 on Tuesday, reaching $117.69. 1,698,190 shares of the stock were exchanged, compared to its average volume of 1,761,661. The stock has a market cap of $18.74 billion, a P/E ratio of -16.03 and a beta of 1.19. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.26. The firm has a 50 day moving average of $134.81 and a two-hundred day moving average of $128.22. Illumina has a 1-year low of $89.00 and a 1-year high of $232.23.
Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of $0.01 by $0.13. The business had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The business's revenue for the quarter was up 3.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.14 EPS. On average, research analysts anticipate that Illumina will post 0.91 EPS for the current year.
Analyst Upgrades and Downgrades
Several equities research analysts have recently commented on the company. OTR Global reissued a "mixed" rating on shares of Illumina in a research note on Wednesday, March 20th. Royal Bank of Canada reissued an "outperform" rating and set a $253.00 price target on shares of Illumina in a research note on Tuesday, April 9th. Scotiabank raised Illumina from a "sector perform" rating to a "sector outperform" rating and set a $185.00 price target on the stock in a research note on Monday, December 18th. Barclays boosted their price target on Illumina from $85.00 to $100.00 and gave the stock an "underweight" rating in a research note on Wednesday, April 10th. Finally, Stephens reaffirmed an "overweight" rating and issued a $170.00 target price on shares of Illumina in a research note on Wednesday, April 10th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $167.70.
Read Our Latest Report on ILMN
Insider Buying and Selling at Illumina
In other Illumina news, CEO Jacob Thaysen acquired 7,330 shares of the stock in a transaction on Thursday, February 22nd. The shares were bought at an average price of $135.29 per share, with a total value of $991,675.70. Following the acquisition, the chief executive officer now owns 14,861 shares of the company's stock, valued at $2,010,544.69. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.17% of the stock is owned by corporate insiders.
Institutional Trading of Illumina
A number of institutional investors and hedge funds have recently made changes to their positions in ILMN. J.P. Morgan Private Wealth Advisors LLC acquired a new stake in Illumina in the 3rd quarter valued at $29,558,000. Aquila Investment Management LLC boosted its position in Illumina by 150.0% in the 4th quarter. Aquila Investment Management LLC now owns 25,000 shares of the life sciences company's stock valued at $3,481,000 after buying an additional 15,000 shares during the last quarter. International Assets Investment Management LLC boosted its position in Illumina by 210.5% in the 4th quarter. International Assets Investment Management LLC now owns 48,194 shares of the life sciences company's stock valued at $6,711,000 after buying an additional 32,672 shares during the last quarter. Weil Company Inc. boosted its position in Illumina by 59.2% in the 3rd quarter. Weil Company Inc. now owns 22,963 shares of the life sciences company's stock valued at $3,152,000 after buying an additional 8,539 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Illumina by 15.0% in the 3rd quarter. Vanguard Group Inc. now owns 17,967,758 shares of the life sciences company's stock valued at $2,466,614,000 after buying an additional 2,336,935 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.
About Illumina
(
Get Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Recommended Stories
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
